ArticleBone marrow transplantation2001

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.

M Bewick et al.PubMed ↗Publisher ↗

No numbers read from the abstract.